Samuel Kintz, PRESIDENT AND CEO at Enliven Therapeutics, Inc. (ELVN), sold 6,000 shares at $19.09 ($116K) on 2025-09-17, disclosed to the SEC on 2025-09-19.
Scheduled sale ($116k) by PRESIDENT AND CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $19.09 | 5,000 | $95K | 82.5% |
| 2 | $20.25 | 1,000 | $20K | 17.5% |
| Total | $19.28 avg | 6,000 | $116K | 100% |
| Filing → |
| ELVN | SELL | 2025-09-30 | $74K | — | Filing → |
| ELVN | SELL | 2025-09-25 | $56K | — | Filing → |
| ELVN | SELL | 2025-08-21 | $30K | — | Filing → |